P
Peter Lanyon
Researcher at Nottingham University Hospitals NHS Trust
Publications - 131
Citations - 5206
Peter Lanyon is an academic researcher from Nottingham University Hospitals NHS Trust. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 33, co-authored 112 publications receiving 3928 citations. Previous affiliations of Peter Lanyon include University of Nottingham & Queen's University.
Papers
More filters
Journal ArticleDOI
Modification and validation of the Birmingham Vasculitis Activity Score (version 3)
Chetan Mukhtyar,Robert J. Lee,Denise Brown,David Carruthers,Bhaskar Dasgupta,Shirish Dubey,Oliver Flossmann,C Hall,Jane Hollywood,David Jayne,Rachel B Jones,Peter Lanyon,Alice Muir,David Scott,Laurel Young,Raashid Luqmani +15 more
TL;DR: The new version of Birmingham Vasculitis Activity score (v.3) demonstrates convergence with BVAS(v.2), treatment decision, physician global assessment of disease activity, vasculitis activity index and C-reactive protein and is repeatable, reproducible and sensitive to change.
Journal ArticleDOI
The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies.
Frances Rees,Frances Rees,Michael Doherty,Matthew J. Grainge,Peter Lanyon,Peter Lanyon,Weiya Zhang +6 more
TL;DR: There are worldwide differences in the incidence and prevalence of SLE that vary with sex, age, ethnicity and time and further study of genetic and environmental risk factors may explain the reasons for these differences.
Journal ArticleDOI
The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012
TL;DR: The incidence of SLE has been declining but the prevalence has been increasing in the UK in recent years, and people of Black Caribbean ethnicity had the highest incidence and prevalence.
Journal ArticleDOI
Radiographic assessment of symptomatic knee osteoarthritis in the community: definitions and normal joint space.
TL;DR: Osteophyte is the radiographic feature that associates best with knee pain among men and women in the community and there is not a biological cut off for joint space width below which the likelihood of knee pain markedly increases.
Journal ArticleDOI
Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.
Simon J. Bowman,Colin C Everett,John O’Dwyer,Paul Emery,Costantino Pitzalis,Wan-Fai Ng,Colin T. Pease,Elizabeth Price,Nurhan Sutcliffe,Nagui Gendi,Frances Hall,Sharon Ruddock,Catherine Fernandez,Catherine Reynolds,Claire Hulme,Kevin A. Davies,Christopher J Edwards,Peter Lanyon,Robert J. Moots,Euthalia Roussou,Ian Giles,Linda D. Sharples,Michele Bombardieri +22 more
TL;DR: In this paper, the authors investigated whether rituximab, an anti-B cell therapy, improves symptoms of fatigue and oral dryness in patients with primary Sjogren's syndrome (SS).